Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients:...
Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Nafamostat mesylate is an anticoagulant used for critically ill patients during continuous kidney replacement therapy (CKRT), characterised by its short half-life. However, its optimal dosage remains unclear. This study aimed to explore the optimal dosage of nafamostat mesylate during CKRT.
We conducted a two-centre observational study. We scree...
Alternative Titles
Full title
Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_a84bd85e7d294691b2cdae00637a191e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a84bd85e7d294691b2cdae00637a191e
Other Identifiers
ISSN
1471-2369
E-ISSN
1471-2369
DOI
10.1186/s12882-024-03506-0
